We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Mechanism of action of rituximab. rituximab can induce cell death via several mechanisms. Antigen-antibody (Ag-Ab) complexes formation and Fc-Fc gamma receptor (FcγR) complexes binding to CD20 can induce programmed cell death (PCD) by triggering the intrinsic pathway of apoptotic caspase activation via the Bcl-2 family proteins (Signal A) and mitochondrial outer membrane permeabilisation (MOMP) (Signal B). in antibody-dependent cell-mediated-cytotoxicity (ADCC), Rituximab recruits effector cells by binding to their Fcγ receptors and this triggers effector cells to release of pre-forming proteins and proteases thus resulting in target cell death. In antibody-dependent cellular-phagocytosis (ADCP) Rituximab recruits monocytes/macrophages by binding to their Fcγ receptors and this results in engulfment of antibody coated tumor cells. In complement-mediated cytotoxicity (CDC), rituximab activates complement cascade and generates membrane attack complexes and as a result induce cell death. MOR, mechanisms of resistance; sCD20, soluble CD20; Cir, complement inhibitory receptors.

Ezogelin Oflazoglu, et al. MAbs. 2010 Jan-Feb;2(1):14-19.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk